Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

    September 21, 2023

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

      September 21, 2023

      Liftoff for the Biotech Launch Pad

      September 20, 2023

      Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

      September 19, 2023

      Machine learning biotech raises $273 million in rare successful late-stage round

      September 15, 2023

      Discover the synergy between biotech, medtech and digital health in Ghent, a European technology capital

      September 14, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’
    Bio Technology

    Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’

    yourbiotechBy yourbiotechDecember 8, 2022Updated:December 8, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    A veteran biotechnology executive, Jonas had spent nine years at neuroscience drug developer Sage Therapeutics. Hired as CEO in 2013, Jonas helped build Sage from a tiny startup into a large, publicly traded company that brought to market the first approved drug for postpartum depression. A second depression drug that’s part of a $3 billion alliance with Biogen could be submitted to regulators this month.

    But as Sage grew, Jonas said he yearned for the company’s early days. The priorities and job description of top executives change as small biotechs grow and evolve. Early scientific research and clinical development give way to regulatory discussions and commercial planning. There are more shareholders to appease, bigger budgets to manage and profits to build.

    “I missed the startup environment,” Jonas said in an interview.

    SPONSORED by T-Mobile
    What to look out for in the next era of retail
    Retailers need to rethink their retail space and reimagine their digital infrastructure with the right technology.
    Sage had suffered setbacks, too. There were drug failures and strategic changes, most notably a negative readout in 2019 that erased much of Sage’s market value and led the company to lay off more than half its workforce.

    That year, Jonas began laying the groundwork for his exit. In December 2020, he was named “chief innovation officer” as Sage brought in Barry Greene, a longtime Alnylam executive, as its new leader. That title gave Jonas freedom to focus on Sage’s pipeline and guide Greene during the transition, he said.

    “Two years was good enough for that,” he added. “I did my job.”

    Now Jonas has returned to the startup world, but in a much different role. Last month, he left Sage to become the CEO of Abio-X, a young Boston-area biotech incubator funded by Asia-based private equity firm CBC Group. From that perch, Jonas has $150 million to spend forming and molding a group of new drugmakers. Two of them, Adcentrx Therapeutics and Ensem Therapeutics, had already raised sizable funding rounds before he arrived. Another as-yet-undisclosed company is in the works, he says, with more to come.

    BioPharma Dive spoke with Jonas about his decision to join Abio-X and how he aims to compete in an arena full of experienced venture capitalists and rival incubators. This conversation has been lightly edited and condensed for clarity.

    BIOPHARMA DIVE: How did you end up running an incubator? Why not retire instead?

    JEFF JONAS: We all have these personal odysseys. I just realized that I missed the startup environment, and I also missed running things. I really enjoy science. I really believe that what our industry does is important. It’s one of those places where you can benefit people, remain active and add value. I just didn’t want to play golf every day.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleEntact Bio Draws $81M Financing for Protein Enhancement Platform
    Next Article Omicron boosters are weaker against BQ.1.1 subvariant that is rising in U.S., study finds
    yourbiotech
    • Website

    Related Posts

    Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

    September 21, 2023

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023

    Machine learning biotech raises $273 million in rare successful late-stage round

    September 15, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.